Integrated Phenotyping of the Gut-plAtelet-Liver AXIS in the Progression of Chronic Liver Disease (iGAL-AXIS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

132 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-30

Study Completion Date

2025-12-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective of the study Our working hypothesis is that platelets activated by gut-derived metabolites dock in the liver of NAFLD patients and amplify the inflammatory state by releasing pro-inflammatory cytokines/chemokines, which in turn recruit and activate leukocytes in the liver sinusoids. Combined stimuli from leukocytes and platelets would then lead to metabolic reprogramming of hepatocytes, progression to NASH and eventually cirrhosis.

To test this hypothesis, the investigators propose 2 objectives. Primary objective: To identify platelet features that correlate with liver disease progression.

Secondary objective: To study the mechanistic relationship between gut dysbiosis, metabolome composition, inflammation, and platelet activation in chronic liver disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cytokines and the Risk of Infection in Liver Cirrhosis

NCT00857181

Liver Cirrhosis

TERMINATED

Immunomediated Non-alcoholic SteaTohepatitis; Prevalence and Characterization. INSTInCT Study

NCT03760172

Main Hypothesis is That in the NASH Associated to IMIDs, to Different Phenotypes co Exist

UNKNOWN

Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors

NCT07238114

Liver Cirrhosis Viral Pneumonia Fungal Infection +2 more

ACTIVE_NOT_RECRUITING

Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease

NCT06691529

Fatty Liver Disease Chronic Glomerular Disease

NOT_YET_RECRUITING

Prospective Studies on Immunopathogenesis of Liver Fibrosis

NCT04943978

Chronic Liver Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver diseases and is now considered a global health problem. NAFLD is a spectrum of diseases ranging from simple hepatic steatosis (NAFL) to non-alcoholic Steatohepatitis (NASH). Over time, NAFLD may progress to cirrhosis and ultimately to hepatocellular carcinoma (HCC). The gold-standard for diagnosis is liver biopsy that allows to discriminate different types of steatosis, characterized by the accumulation of lipid droplets of different sizes in hepatocytes, with the largest droplets associated with the development of fibrosis and the severity of the disease. Future studies are needed to identify non- invasive diagnostic approaches alternative to liver biopsy. NAFLD is not considered a "hepato-centric" condition anymore. Bi-directional metabolic and immune lanes of communication with other organs, such as the gut, have been decoded. Gut dysbiosis, increased gut permeability and bacterial translocation within portal circulation have been reported in NAFLD, suggesting that the gut-liver axis represents a source of systemic and hepatic inflammation.

Many studies suggest that platelets may be the link between gut and liver dysfunction. Beyond their role in hemostasis platelets can sense PAMPs and DAMPs and actively participate in the inflammatory response and in tissue remodeling, by releasing bioactive molecules and by interacting with leukocytes. Gut-derived metabolites and bacterial endotoxins promote platelet hyper-reactivity and recent studies point to an important role of platelets in regulating chronic liver inflammation. Platelet-derived cytokines, such as TGF-β, PDGF-β and CXCL4 promote hepatic fibrosis, and platelet count has been used as a surrogate marker of liver fibrosis FIB-4 index). Platelet number and platelet aggregates are increased in liver sinusoids of NASH patients and colocalise with neutrophil extracellular traps (NETs). In mice it was shown that platelet colonization of the liver is a critical step for the recruitment of CD8+ T cells and NKT cells, which drive NASH progression through the release of cytokines and the metabolic reprogramming of hepatocytes. In humans, inhibition of platelets with a combination of aspirin and clopidogrel has been shown to reduce the development of NASH and subsequent progression to cirrhosis and HCC. Mechanistic insights suggest that the role of platelets in NAFLD progression is mediated through the interaction with immune cells.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Fatty Liver Disease (NAFLD) NASH - Nonalcoholic Steatohepatitis Cirrhosis Control Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

* age\&gt;18;
* NAFLD patients according to EASL Guidelines 2016.

Exclusion Criteria

* decompensated cirrhosis, other causes of chronic liver disease (infectious and immune-mediated); malabsorption syndromes (i.e., celiac disease, food allergy, small bowel bacterial overgrowth);
* inflammatory bowel disease; previous GI surgery;
* immunodeficiencies; neurological handicaps;
* use of NSAIDs, antibiotics, probiotics, or anti-secretory drugs within the 2 months preceding enrollment;
* abnormality of hemostasis and thrombosis; malignancies.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes